Source ID: D26
Original URL: https://www.sec.gov/Archives/edgar/data/1776985/000177698526000054/a991bntx_q22026pressreleas.htm
Title (supplied): BioNTech Q2 2026 financial results, SEC exhibit
Source date (retained): 2026-08-04
Data date (retained): 2026-06-30
Checked at: 2026-10-07T18:42:41+08:00
Timezone: Asia/Taipei
Checked-at meaning: current review of returned public web-tool extraction; not the historical network-fetch timestamp.
Retrieval mode: public_web_tool_readback_prior_ref; prior saved web_ref was opened and returned the specified original public URL.
Prior web ref: turn52view2
Current web ref: turn130view0
Read level: relevant primary-source paragraphs in web text extraction; complete original HTML/PDF bytes not saved or hashed.
Original network read time: null; not exposed by the tool. Original artifact SHA256: null.
Locator: SEC exhibit company earnings release; retrieved lines 24 and ADC section 264–279.
Minimum verbatim excerpts (aggregate <=25 English words):
- current event accrual projections
- expected in the fourth quarter 2026
Excerpt word count: 10
Factual extraction (values, dates, statuses; not additional prose quotations):
[
  {
    "field": "release_date",
    "original_value": "August 4, 2026",
    "unit_or_role": "calendar date",
    "locator": "L24"
  },
  {
    "field": "reporting_period_end",
    "original_value": "June 30, 2026",
    "unit_or_role": "calendar date",
    "locator": "L24"
  },
  {
    "field": "DYNASTY_Breast02_primary_analysis_expectation",
    "original_value": "fourth quarter 2026",
    "unit_or_role": "event-accrual-based company expectation",
    "locator": "L276"
  },
  {
    "field": "BNT323_alias",
    "original_value": "DB-1303 / trastuzumab pamirtecan",
    "unit_or_role": "asset alias",
    "locator": "L265"
  },
  {
    "field": "BNT324_alias",
    "original_value": "DB-1311 / elfetabart drozuntecan",
    "unit_or_role": "asset alias",
    "locator": "L278"
  }
]
Support scope: SEC-hosted company release specifies event-accrual-dependent Q4 2026 DYNASTY-Breast02 primary-analysis expectation and identifies BNT323/DB-1303 and BNT324/DB-1311 collaborations with Duality. This does not establish option exercise or that a readout occurred.
Precise gap: No additional source-specific factual gap found within the assigned contribution; multi-source rows retain their other citations.
Source/data dates are supplied baseline metadata, not replaced by this check time. No alternate route, login, headers, private endpoint or payment used.
This small evidence record is an excerpt/factual extraction, not a saved full article.